References
- JordanVCChemoprevention of breast cancer with selective oestrogen-receptor modulatorsNat Rev Cancer200771465317186017
- CuzickJPowlesTVeronesiUOverview of the main outcomes in breast-cancer prevention trialsLancet2003361935429630012559863
- GoetzMPRaeJMSumanVJPharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashesJ Clin Oncol200523369312931816361630
- GoetzMPKnoxSKSumanVJThe impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifenBreast Cancer Res Treat2007101111312117115111
- WuXHawseJRSubramaniamMGoetzMPIngleJNSpelsbergTCThe tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cellsCancer Res20096951722172719244106
- FisherBCostantinoJPWickerhamDLTamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJ Natl Cancer Inst19989018137113889747868
- Mauvais-JavisPBaudotNCastaigneDBanzetPKuttennFtrans-4-Hydroxytamoxifen concentration and metabolism after local percutaneous administration to human breastCancer Res1986463152115253943109
- PujolHGiraultJRouanetPPhase I study of percutaneous 4-hydroxy-tamoxifen with analyses of 4-hydroxy-tamoxifen concentrations in breast cancer and normal breast tissueCancer Chemother Pharmacol19953664934987554041
- RouanetPLinares-CruzGDravetFNeoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifenJ Clin Oncol200523132980298715860853
- BronaughRLStewartRFMethods for in vitro percutaneous absorption studies. VI: preparation of the barrier layerJ Pharm Sci19867554874913735088
- ManselRGoyalANestourELMasini-EteveVO’ConnellKA phase II trial of Afimoxifene (4-hydroxytamoxifen gel) for cyclical mastalgia in premenopausal womenBreast Cancer Res Treat2007106338939717351746
- LimYCDestaZFlockhartDASkaarTCEndoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifenCancer Chemother Pharmacol200555547147815685451
- LimYCLiLDestaZEndoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cellsJ Pharmacol Exp Ther2006318250351216690721
- WilliamsACBarryBWPenetration enhancersAdv Drug Deliv Rev200456560361815019749
- KimDDKimJLChienYWMutual hairless rat skin permeation-enhancing effect of ethanol/water system and oleic acidJ Pharm Sci19968511119111958923324
- KimMJDohHJChoiMKSkin permeation enhancement of diclofenac by fatty acidsDrug Deliv200815637337918686081
- GoodmanMBarryBWAction of penetration enhancers on human skin as assessed by the permeation of model drugs 5-fluorouracil and estradiol. I. Infinite dose techniqueJ Invest Dermatol19889143233273171212
- FangJYHwangTLLeuYLEffect of enhancers and retarders on percutaneous absorption of flurbiprofen from hydrogelsInt J Pharm2003250231332512527159
- YuBDongCYSoPTBlankschteinDLangerRIn vitro visualization and quantification of oleic acid induced changes in transdermal transport using two-photon fluorescence microscopyJ Invest Dermatol20011171162511442745
- OgisoTPakuTIwakiMTaninoTPercutaneous penetration of fluorescein isothiocyanate-dextrans and the mechanism for enhancement effect of enhancers on the intercellular penetrationBiol Pharm Bull19951811156615718593481
- CosmanFBaz-HechtMCushmanMShort-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literatureThromb Res2005116111315850603
- CuzickJForbesJEdwardsRFirst results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trialLancet2002360933681782412243915
- KhanSARogersMAKhuranaKKMeguidMMNumannPJEstrogen receptor expression in benign breast epithelium and breast cancer risk [see comments]J Natl Cancer Inst199890137429428781
- RickettsDTurnbullLRyallGEstrogen and progesterone receptors in the normal female breastCancer Res199151181718222004366
- AckermanABKesslerGGyorfTTsouHCGottliebGJContrary view: the breast is not an organ per se, but a distinctive region of skin and subcutaneous tissueAm J Dermatopathol200729221121817414452
- PovoskiSPOlsenJOYoungDCProspective randomized trial comparing intradermal, intraparenchymal, and subareolar injection routes for sentinel lymph node mapping and biopsy in breast cancerAnn Surg Oncol2006132101116372150
- KlimbergVSRubioITHenryRCowanCColvertMKorourianSSubareolar versus peritumoral injection for location of the sentinel lymph nodeAnn Surg1999229686086410363900
- LienEASolheimEUelandPMDistribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatmentCancer Res19915118483748441893376